FDA data Registry peer set 1 peer

Alternatives to apremilast

1 same-class SPL records vs apremilast - uses, FAERS reaction fields, and OTC/Rx flags from public FDA sources.

Brand: Otezla

PDE4 Inhibitor Prescription 1 alternative found

How to read a high-report FAERS peer set

apremilast ranks in the upper FAERS-volume third of the corpus (#45 of 524); 1 same-class peers are listed for field comparison only. Labeled indication field for apremilast: Apremilast is used to treat active psoriatic arthritis in adults and children 6 years and older.

Top FAERS reaction fields for apremilast total 125,731 reports across 10 reactions, set beside roflumilast. Counts are exposure-weighted submissions, not per-patient risk.

About apremilast

Apremilast (Otezla/Otezla XR) is a medicine that can help adults and children manage psoriatic arthritis and psoriasis. It can also help adults with oral ulcers from Behçet's Disease.

Used for: Apremilast is used to treat active psoriatic arthritis in adults and children 6 years and older. It also treats plaque psoriasis in adults and children 6 years and older who may use light therapy or other medicines that affect the whole body. Apremilast can also treat oral ulcers caused by Behçet's Disease in adults.

1 PDE4 Inhibitor peers (wide set)

Compare apremilast vs roflumilast side-by-side →

apremilast vs roflumilast · FAERS reaction fields

FAERS top-reaction field "Diarrhoea" shows the widest count spread between apremilast and roflumilast in this extract (23,748-report gap on that field). Counts are exposure-weighted submissions, not prevalence rates.

Side Effect apremilast roflumilast
Diarrhoea 24,315 567
Nausea 21,927 465
Psoriasis 20,247 -
Headache 17,679 404
Abdominal Discomfort 8,065 -
Psoriatic Arthropathy 7,852 -
Pain 6,595 -
Rash 6,479 -

"-" means no reports for that reaction. Report counts reflect total FAERS submissions, not prevalence rates.

apremilast FAERS volume vs class peers

FAERS volume band

apremilast is FAERS corpus rank #45 of 524 (high volume tercile). Top-reaction field total: 125,731.

Frequently Asked Questions

Where does apremilast sit in FAERS report volume vs PDE4 Inhibitor peers?
apremilast ranks #45 of 524 drugs by FAERS top-reaction report volume (high volume tercile). Top-reaction fields total 125,731 submissions in this extract, exposure-weighted counts, not per-patient risk.

Registry note: FAERS counts are voluntary reports and do not establish causation or risk rates. This information is for educational purposes only and is not a substitute for professional medical advice. Do not stop or change your medication without talking to your doctor or pharmacist.

Full apremilast profile →

Field note for apremilast: see also the generic vs brand label guide when reading Otezla SPL strings.